CD274 and neoplasm: Currently, PD-1/PD-L1 inhibitor therapy has been approved by the U.S. Food and Drug Administration (FDA) for treating TNBC, but few patients received durable clinical responses as a result of the limitation of immunosuppressive tumor microenvironment (TME) (2).